DuoGenic StemCells corporation – Trademark Portfolio
Entity Type: 03
DuoGenic StemCells corporation holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 44 (Medical Services) — 3 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 6 trademarks are registered. Notable registered marks include DUOESY and DUOGENIC STEMCELLS. The owner is based in Taichung City.
No. 18, Ln. 10, Taiping 21st St.
Taiping Dist.
Taichung City 411021 , TW
Showing of trademarks Trademarks
Trademark Classifications
DuoGenic StemCells corporation's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does DuoGenic StemCells corporation have?
DuoGenic StemCells corporation has 6 U.S. trademarks filed with the USPTO. Of these, 6 registered.
What trademark classes does DuoGenic StemCells corporation file in?
DuoGenic StemCells corporation files trademarks across 2 Nice Classification classes. The most active classes are Class 44 (Medical Services), Class 5 (Pharmaceuticals). Class 44 covers medical services; veterinary services; hygienic and beauty care for human beings or animals.
What are DuoGenic StemCells corporation's most well-known trademarks?
DuoGenic StemCells corporation's registered trademark portfolio includes well-known marks such as DUOESY and DUOGENIC STEMCELLS. These are among 6 currently registered trademarks in the portfolio.
What is DuoGenic StemCells corporation's trademark registration success rate?
DuoGenic StemCells corporation has a 100% trademark registration rate, with 6 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.